Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Broly

Showing results (21-30 of 68) with videos related to

Pageof 7
Sort By:
Human Psychopharmacology|July 15, 2004
Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patientsP Vandel, E Haffen, S Nezelof, et al.
European Journal of Clinical Pharmacology|January 1, 1992
Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteersT Graf, F Broly, F Hoffmann, et al.
The Journal of Pediatrics|April 1, 1987
Simultaneous administration of caffeine and phenobarbitone in infants with apneaM Lhermitte, N Houdret, F Broly, et al.
Carcinogenesis|October 1, 1996
Influence of a mutation reducing the catalytic activity of the cytochrome P450 CYP2D6 on lung cancer susceptibilityM Legrand, I Stucker, D Marez, et al.
Italian Journal of Pediatrics|October 11, 2022
A PMM2-CDG caused by an A108V mutation associated with a heterozygous 70 kilobases deletion case reportE Lebredonchel, A Riquet, D Neut, et al.
Pharmacogenetics|October 1, 1995
A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotypeD Marez, N Sabbagh, M Legrand, et al.
Pharmacogenetics|April 1, 1997
NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosusN Sabbagh, E Delaporte, D Marez, et al.
Human Genetics|May 1, 1996
An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteineD Marez, M Legrand, N Sabbagh, et al.
Pharmacogenetics|September 2, 1999
A rare G2061 insertion affecting the open reading frame of CYP2D6 and responsible for the poor metabolizer phenotypeD Marez-Allorge, S W Ellis, J M Lo Guidice, et al.
Pharmacopsychiatry|December 22, 1999
Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotypeE Haffen, P Vandel, F Broly, et al.
Pageof 7

Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
Human Psychopharmacology|July 15, 2004
Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patientsP Vandel, E Haffen, S Nezelof, et al.
European Journal of Clinical Pharmacology|January 1, 1992
Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteersT Graf, F Broly, F Hoffmann, et al.
The Journal of Pediatrics|April 1, 1987
Simultaneous administration of caffeine and phenobarbitone in infants with apneaM Lhermitte, N Houdret, F Broly, et al.
Carcinogenesis|October 1, 1996
Influence of a mutation reducing the catalytic activity of the cytochrome P450 CYP2D6 on lung cancer susceptibilityM Legrand, I Stucker, D Marez, et al.
Italian Journal of Pediatrics|October 11, 2022
A PMM2-CDG caused by an A108V mutation associated with a heterozygous 70 kilobases deletion case reportE Lebredonchel, A Riquet, D Neut, et al.
Pharmacogenetics|October 1, 1995
A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotypeD Marez, N Sabbagh, M Legrand, et al.
Pharmacogenetics|April 1, 1997
NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosusN Sabbagh, E Delaporte, D Marez, et al.
Human Genetics|May 1, 1996
An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteineD Marez, M Legrand, N Sabbagh, et al.
Pharmacogenetics|September 2, 1999
A rare G2061 insertion affecting the open reading frame of CYP2D6 and responsible for the poor metabolizer phenotypeD Marez-Allorge, S W Ellis, J M Lo Guidice, et al.
Pharmacopsychiatry|December 22, 1999
Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotypeE Haffen, P Vandel, F Broly, et al.
Pageof 7